Clinipace Worldwide Acquires Paragon Biomedical, Inc.

Clinipace Worldwide, a global digital contract research organization (dCRO), and Paragon Biomedical, Inc., a global, full-service contract research organization (CRO), today jointly announced a definitive merger agreement under which Clinipace Worldwide has acquired all outstanding shares of the privately-held, Irvine, CA-based company and its subsidiaries. The merger will significantly expand Clinipace Worldwide’s therapeutic expertise, site management capabilities, and clinical operations.  In addition, the company extends its global footprint with the addition of offices in Irvine, California, High Wycombe, United Kingdom, and Trivandrum, India.  

“Paragon is an ideal partner to achieve our common long-term goals to drive innovation in clinical research through a technology-amplified service platform.  Bringing our two companies together provides the foundation for a more compelling service offering, supported by a substantial body of work spanning 20 years, a great reputation for quality, a differentiated technology-enabled clinical operations platform, a strong site management organization, and an experienced management team,” said Jeff Williams, CEO, Clinipace Worldwide.  “We offer a formidable and globally integrated array of clinical development services along with strategic product development, regulatory, and GxP/CMC/QA consultancy”.

Bringing these organizations together strengthens Clinipace Worldwide’s already strong oncology franchise with additional therapeutic expertise in the areas of cardiovascular, immunology, infectious diseases, central nervous system, respiratory, dermatology, and medical device clinical research services.  Clinipace Worldwide also greatly expands its global footprint with a total of 12 offices in eight countries.